Passa al contenuto
Merck

Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex.

Neurobiology of disease (2014-10-05)
Tiziana Rubino, Pamela Prini, Fabiana Piscitelli, Erica Zamberletti, Massimo Trusel, Miriam Melis, Claudia Sagheddu, Alessia Ligresti, Raffaella Tonini, Vincenzo Di Marzo, Daniela Parolaro
ABSTRACT

Current concepts suggest that exposure to THC during adolescence may act as a risk factor for the development of psychiatric disorders later in life. However, the molecular underpinnings of this vulnerability are still poorly understood. To analyze this, we investigated whether and how THC exposure in female rats interferes with different maturational events occurring in the prefrontal cortex during adolescence through biochemical, pharmacological and electrophysiological means. We found that the endocannabinoid system undergoes maturational processes during adolescence and that THC exposure disrupts them, leading to impairment of both endocannabinoid signaling and endocannabinoid-mediated LTD in the adult prefrontal cortex. THC also altered the maturational fluctuations of NMDA subunits, leading to larger amounts of gluN2B at adulthood. Adult animals exposed to THC during adolescence also showed increased AMPA gluA1 with no changes in gluA2 subunits. Finally, adolescent THC exposure altered cognition at adulthood. All these effects seem to be triggered by the disruption of the physiological role played by the endocannabinoid system during adolescence. Indeed, blockade of CB1 receptors from early to late adolescence seems to prevent the occurrence of pruning at glutamatergic synapses. These results suggest that vulnerability of adolescent female rats to long-lasting THC adverse effects might partly reside in disruption of the pivotal role played by the endocannabinoid system in the prefrontal cortex maturation.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Dimetil solfossido, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Dimetil solfossido, ACS reagent, ≥99.9%
Sigma-Aldrich
Dimetil solfossido, Molecular Biology
Sigma-Aldrich
Dimetil solfossido, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Dimetil solfossido, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Dietiletere, anhydrous, ACS reagent, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
Dimetil solfossido, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Dimetil solfossido, anhydrous, ≥99.9%
Sigma-Aldrich
Dietiletere, suitable for HPLC, ≥99.9%, inhibitor-free
Sigma-Aldrich
Dietiletere, ACS reagent, anhydrous, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
Dimetil solfossido, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Dimetil solfossido, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
Dietiletere, contains BHT as inhibitor, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
Sodium phosphate, 96%
Sigma-Aldrich
Dimetil solfossido, BioUltra, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
Dietiletere, contains 1 ppm BHT as inhibitor, anhydrous, ≥99.7%
Sigma-Aldrich
Dimetil solfossido, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
Dietiletere
Sigma-Aldrich
Dimetil solfossido, PCR Reagent
Sigma-Aldrich
Dietiletere, reagent grade, ≥98%, contains ≤2% ethanol and ≤10ppm BHT as inhibitor
Sigma-Aldrich
Dietiletere, ACS reagent, ≥98.0%, contains ≤2% ethanol and ≤10ppm BHT as inhibitor
Sigma-Aldrich
Dimetil solfossido, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
Dietiletere, puriss., contains ~5 mg/L 2,6-di-tert.-butyl-4-methylphenol as stabilizer, meets analytical specification of Ph. Eur., BP, ≥99.5% (GC)
Supelco
Dietiletere, analytical standard
Supelco
Dimetil solfossido, analytical standard
Sigma-Aldrich
AM251, >98% (HPLC), solid
Supelco
Dimetil solfossido, for inorganic trace analysis, ≥99.99995% (metals basis)
USP
Dimetil solfossido, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Dimethyl sulfoxide solution, 50 wt. % in H2O
Dimetil solfossido, European Pharmacopoeia (EP) Reference Standard